St. Jude Medical Ab

St Jude Medical, Atrial Fibrillation Division, Inc

Pacesetter Ab

Pacesetter, Inc.

Karin Järverud

Anders Björling

Nils Holmström

Sven-Erik Hedberg

Kjell Noren

Andreas Blomqvist

Anders Bjorling

Tomas Svensson

Stefan Hjelm

Malin Hollmark

Kenth A Nilsson

Hans G Strandberg

Asa Uhrenius

Göran Budgifvars

Xiaoyi Min

Rupinder Bharmi

Richard P Williamson

Martin Obel

Kjell Norén

Jay Snell

Staffan Bowald

Karin Ljungström

Berit Larsson

Michael Broome

Andreas Karlsson

Anna-Karin Johansson

Per Lagercrantz

Leif Lindkvist

Michael Broomé

Andreas Blomovist

Cecilia Emanuelsson

Cecilia Emmanuelsson

Sven Erik Hedberg

Michael Broomè

Leif Lindqvist

Urban Lönn

Anders BJÖRLING

In response to local or systemic inflammation in a patient, photobiomodulation therapy is applied to a cardiac location to reduce the risk and/or occurrence of cardiac arrhythmia. Once inflammation is identified, photobiomodulation therapy can be applied in any suitable fashion (e.g., via a catheter- or transesophageal probe-mounted photoemitter, via an externally-applied photoemitter, or via photoemitter incorporated into an implantable medical device). Photobiomodulation therapy can also be employed to good advantage in conjunction with non-photobiomodulation therapy (e.g., traditional cardiac rhythm management therapies).

Method of reducing the occurrence of arrhythmias via photobiomodulation and apparatus for same

A patient-specific hemodyanmic status model is determined from impedance data collected during periods of normal and abnormal hemodynamic status by deriving parameter values of a set of multiple impedance-derivable parameters from impedance signals collected during periods of normal hemodynamic status and in connection with periods of abnormal hemodynamic status. The parameter values are employed to estimate coefficients of a linear parametric status model. These coefficients can then be used together with parameter values determined from impedance signals determined during status assessment periods in order to determine a current hemdoynamic status of the patient.

Hemodynamic status assessment

An implantable medical device has an impedance processor for determining atrial impedance data reflective of the cardiogenic impedance of an atrium of a heart during diastole and/or systole of heart cycle. Ventricular impedance data reflective of the cardiogenic impedance of a ventricle during diastole and/or systole are also determined. The determined impedance data are processed by a representation processor for estimating a diastolic and/or a systolic atrial impedance representation and a diastolic and/or a systolic ventricular impedance representation. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of at least one heart valve based on the estimated atrial and ventricular impedance representations.

System for determining the condition of a heart valve

Method, implantable medical device, and system for determining the condition of a heart valve

An implantable medical device has an impedance processor that determines impedance data reflective of the transvalvular impedance of a heart valve of a heart during a heart cycle. The determined impedance data are processed by a representation processor that estimates diastolic and systolic transvalvular impedance representations. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation and/or stenosis, of the heart valve based on the estimated diastolic and systolic transvalvular impedance representations.

A first ventricle is stimulated at a stimulation site, a point of time for arrival at the AV node for at least one depolarization wave resulting from the stimulation is estimated and a first activation time interval substantially corresponding to the time interval required for at least one depolarization wave to travel from the stimulation site in the first ventricle to the AV node is computed. A similar process is used to compute a second activation time interval for the other ventricle. Based on these activation time intervals and a difference between the intervals, a pacing therapy can be determined.

Method and system for stimulating a heart

An implantable medical device, is designed to collect a signal representative of the electric activity of the heart and determine a cardiogenic impedance signal for at least a portion of the heart. An R-wave detector of the IMD detects the timing of an R-wave during a cardiac cycle based on the signal representative of the electric activity. A minimum detector detects the timing of a cardiogenic impedance minimum in the cardiogenic impedance signal and within a systolic time window of the cardiac cycle. A detected arrhythmia is then classified by the IMD based on the timing of the R-wave detected by the R-wave detector and the timing of the cardiogenic impedance minimum detected by the minimum detector.

Arrhythmia classification

An implantable medical device has an impedance processor that determines impedance data reflective of the transvalvular impedance of a heart valve of a heart during a heart cycle. The determined impedance data are processed by a representation processor that estimates diastolic and systolic transvalvular impedance representations. A condition processor determines the presence of any heart valve malfunction, such as valve regurgitation andor stenosis, of the heart valve based on the estimated diastolic and systolic transvalvular impedance representations.

The present invention relates to an improved medical device and method for accurately and reliably determining a cardiac status of a patient. An implantable medical device, IMD, comprises a sensor arrangement adapted to sense signals related to mechanical activity of the heart and an activity level sensor arrangement adapted to sense an activity level of the patient. Further, the IMD calculates a percentage of left ventricular diastolic time (PLVDT) for a cardiac cycle corresponding to a relation between a diastolic time interval and a cardiac cycle time interval using the determined systolic and diastolic time intervals or a percentage of left ventricular systolic time (PLVST) for a cardiac cycle corresponding to a relation between a systolic interval time interval and a cardiac cycle time interval. A cardiac status is determined based on the calculated PLVDT (or PLVST) and on an activity level of the patient.

Devices and method for determining and monitoring a cardiac status of a patient by using PLVDT or PLVST parameters

In an implantable medical device such as an implantable cardiac defibrillator, and a method for classifying arrhythmia events, IEGM signals are analyzed to detect an arrhythmia event and a respiratory pattern of the patient is sensed. At least one respiratory parameter reflecting characteristics of the respiratory pattern of the patient is determined based on the sensed respiratory pattern and a respiratory measure corresponding to a change of a rate of change of the at least one respiratory parameter is calculated. The detected arrhythmia event is classified based on the respiratory measure and the IEGM signals, wherein arrhythmia events that satisfy at least a first criterion is classified as an arrhythmia event requiring therapy.

Implantable medical device and method for classifying arrhythmia events

An implantable medical device () is configured for generating a cardiogenic impedance signal representative of the cardiogenic impedance of at least a portion of a heart () of a subject () during at least a portion of cardiac cycle. A moment processor () calculates a moment parameter value based on the cardiogenic impedance signal. The moment parameter is representative of a weighted sum of impedance amplitudes within a time window centered at defined time instance within the cardiac cycle. The weights of the impedance amplitudes are further dependent on the length in time between the defined time instance and the point of time of the associated impedance amplitude. The moment parameter is of high diagnostic value and is employed by an arrhythmia classifier () in order to classify a detected arrhythmia of the heart (), such as discriminate between hemodynamically stable or unstable arrhythmias and/or supraventricular or ventricular tachycardia.

Implantable medical device and method comprising means for detecting and classifying an arrhythmia

An implantable coronary perfusion monitoring device for in-vivo determination of a coronary perfusion index (CPI) indicative of the coronary perfusion of a heart has a time measurement unit to determine a blood pressure reflection wave measure t indicating the timely position in the heart cycle of the maximum of a reflected blood pressure wave and in a time period starting at a preset point of time in systole and ending at a local maximum of blood pressure following aortic valve closure and, a diastolic peak pressure measurement unit adapted to determine a diastolic peak blood pressure measure DPP related to diastolic aortic peak pressure and a systolic arterial pressure measurement unit adapted to determine a systolic arterial blood pressure measure SAP related to systolic arterial pressure, and a coronary perfusion index calculating unit adapted to determine said coronary perfusion index CPI as (t&#xb7;DPP)/SAP.

Implantable coronary perfusion monitoring device

In an implantable medical device and a method for monitoring ventricular synchronicity of a heart. In particular, impedance signals are measured and an occurrence of a notch is detected in the impedance signal coincident with a period including a change from rapid to slow filling of a ventricle. The notch is indicated by a first positive slope change in a negative slope in a predetermined time window during a diastolic phase of a cardiac cycle. A degree of synchronicity is determined based on the notch feature, wherein a decreasing notch feature indicates an increased degree of synchronicity in the filling phase of the ventricles.

Implantable medical device and method for monitoring synchronicity of the ventricles of a heart

Growing community of inventors

Solna, Sweden

Karin Järverud